IHL study: Self-checkouts on the rise
NEW YORK — Self-checkout technology continues to rise in importance at retailers in North America, according to a new study by IHL Group.
The "2012 North American Kiosk" study finds that self-checkout shipments are increasing 8% year to year, with self-checkout transactions exceeding $255 billion annually in North America. Transactions at self-service kiosks are growing more than 7% per year in North America, and are expected to exceed $1 trillion by 2014.
The study tracks the shipments, installed base and revenue turn-through kiosks in six different categories: self-checkout, ticketing, check-in, postal, food ordering and other kiosks (which is inclusive of DVD rentals). For more, visit ihlservices.com/ihl/.
Flu vaccinations now available at Supervalu pharmacies
EDEN PRAIRIE, Minn. — Supervalu announced that 10 of its banners will offer flu inoculations this season.
Supervalu pharmacies — including Acme Sav-on, Albertsons Sav-on, Albertsons Osco, Cub, Farm Fresh, Jewel-Osco, Shaw’s Osco, Shop ‘n Save, Shop ‘n Save Osco and Shoppers pharmacies — which operate across 25 states, will administer the traditional flu vaccine, needle-free FluMist nasal spray, Fluzone Intradermal and the Fluzone HD (for patients ages 65 years and older) during regular pharmacy hours. The company said the vaccines, which are administered by specially trained pharmacists, will be able to provide flu vaccinations daily on a walk-in basis or by appointment.
The traditional flu vaccine Fluzone Intradermal and the FluMist nasal spray are available for $29.99 each, while Fluzone HD is available for $59.99. This cost is covered by Medicare Part B and many commercial health plans, Supervalu noted.
For additional details, contact your local store or visit Supervalupharmacies.com.
Merz acquires Cuvposa
GREENSBORO, N.C. — Merz announced it has acquired a medication designed to treat a condition associated with such neurologic conditions as cerebral palsy.
The company said it acquired Cuvposa (glycopyrrolate) oral solution from drug maker Shionogi. Cuvposa, which has been commercially available since April 2011, is the only Food and Drug Administration-approved treatment to reduce chronic severe drooling — a condition known as sialorrhea — in pediatric patients ages 3 to 16 years with neurologic conditions associated with problem drooling, such as cerebral palsy.
"The acquisition of Cuvposa is a promising addition to our neurology business and reflects our commitment to becoming a recognized leader in the treatment of movement disorders and related conditions in the U.S.," Merz president and CEO Bill Humphries said. "Globally, the Merz Pharma Group is deeply committed to offering novel therapeutic options that address the large unmet medical needs that exists within the areas of central nervous system and neurology."